COST-EFFECTIVENESS WILL BE USED AS POSSIBLE FINAL CRITERION WHEN MEDICARE COVERAGE DECISION CAN'T BE MADE WITH OTHER DATA, HCFA STAFFER TELLS PPAC
This article was originally published in The Gray Sheet
Executive Summary
Cost-effectiveness of medical services will play a role in Medicare coverage decisions, but will be applied in a limited and narrowly defined manner, Steven Sheingold, director, technology and special analysis staff in the Bureau of Policy Development for the Health Care Financing Administration, told the Practicing Physicians Advisory Council at an April 22 meeting in Washington, D.C.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.